Tirzepatide Linked to Higher Osteoporosis and Fracture Risk Than Other GLP-1 Drugs

Retrospective cohort study using the TriNetX federated research network. Identified 459,886 patients with type 2 diabetes or obesity who started tirzepatide or other GLP-1 agonists between June 2022 and May 2024. Used 1:1 propensity score matching (66,329 per group) to balance baseline characteristics. Primary outcome was composite of new-onset osteoporosis or fragility fracture over 14 months.

Tirzepatide (Mounjaro/Zepbound) produces the most weight loss of any approved GLP-1-class drug. But rapid, significant weight loss can reduce bone density because bone remodeling doesn't keep pace with fat and muscle loss. This study raises an important safety signal: tirzepatide may carry higher osteoporosis and fracture risk than other GLP-1 drugs, which could be particularly concerning for older patients and postmenopausal women.

As GLP-1 and dual-agonist drugs produce increasingly dramatic weight loss, the downstream effects on bone health are becoming a major concern. Bone density depends partly on mechanical loading from body weight, and rapid weight loss removes that stimulus. If tirzepatide's bone risk is confirmed in prospective studies, bone density monitoring and protective strategies (resistance exercise, calcium/vitamin D, possibly bone-sparing medications) may need to become standard alongside weight loss drug prescriptions.

This is an observational study — it cannot prove tirzepatide directly causes bone loss, only that there's an association. Residual confounding is possible despite propensity score matching. Tirzepatide users may have higher BMI at baseline (since tirzepatide is often reserved for more severe obesity), which could influence fracture detection. The 14-month follow-up may be too short to capture the full fracture risk. The TriNetX database relies on diagnosis codes, which may have coding variability.